


# By the Numbers: Biosimilars

Section Editor: The ISPOR Student Network

## DISTRIBUTION OF APPROVED BIOSIMILARS BY THERAPEUTIC AREA, FDA VS EMA

Therapeutic Area	FDA <sup>1</sup>	EMA <sup>2</sup>
Rheumatology	40%	27%
Oncology	20%	22%
Infectious diseases	10%	20%
Hematology	10%	12%
Endocrinology	0%	10%
Gynecology	0%	5%
Gastroenterology	20%	0%
Cardiology	0%	2%
Medical genetics	0%	2%

## TIMELINE FOR BIOSIMILARS<sup>1,2,3</sup>



## STAKEHOLDER PERSPECTIVES ON BIOSIMILARS

### PHYSICIANS' PERSPECTIVE<sup>4,5</sup>

- 80% are ready to consider pharmacy-level substitution of biologics with biosimilars
- 33% of patients are not confident about biosimilars even when prescribed and explained by the treating physician
- 17% feel biosimilars will become the norm in the next 3 years

### PATIENTS' PERSPECTIVE<sup>6,7</sup>

- 90% patients believe that they had the right to make an informed choice about their treatment and did not support automatic substitution of a biosimilar for a reference product.
- 75% were concerned about the extrapolation of indications for biosimilars

### PAYER PERSPECTIVE<sup>8</sup>

- 88% believe that biosimilars will reduce specialty drug prices
- 80% consider biosimilars to be lower-cost branded options and not generics
- UK payers expect biosimilar market share to be 80% in next 5 years

Contributors: Gary O'Brien, University College Cork; Aakash Gandhi, University of Maryland; Jayesh Patel, West Virginia University; Simrun Grewal, University of Washington; Koen Degeling, University of Twente

<sup>1</sup> <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580432.htm>

<sup>2</sup> [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general\\_content\\_001832.jsp](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_001832.jsp)

<sup>3</sup> <https://www.slideshare.net/smallworldsocial/timeline-47574081>

<sup>4</sup> InCrowd Survey: Nearly Half of US Physicians Say They Will Prescribe More Biosimilars, Boston, MA, March 3, 2016. Available at: <https://incrowdnow.com/press-release/nearly-half-of-us-physicians-say-they-will-prescribe-more-biosimilars-according-to-new-data-from-incrowd/>

<sup>5</sup> Cohen H, Beydoun D, Chien D, et al. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. *Adv Ther.* 2016;33(12):2160-2172.

<sup>6</sup> Peyrin-Biroulet L, Länfors S, Roblin X, Danese S, Avedano L. Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations. *J Crohn's Colitis.* 2017;11(1):128-133. doi:10.1093/ecco-ccj/cjw138 2.

<sup>7</sup> Patient Views on Similar Biologic Medicines: "No Forced Change". Cision Canada. Toronto, Canada, July, 2017. Available at: <http://www.newswire.ca/news-releases/patient-views-on-similar-biologic-medicines-no-forced-change-636923953.html>

<sup>8</sup> How Do US Payers View Biosimilars From a Cost Perspective? The Center for Biosimilar Staff, December 2016. Available at: <http://www.centerforbiosimilars.com/news/how-do-us-payers-view-biosimilars-from-a-cost-perspective>